Regional Chemotherapy for Bladder Neoplasms Using Continuous Intravesical Infusion of Doxorubicin: Impact of Concomitant Administration of Dimethyl Sulfoxide on Drug Absorption and Antitumor Activity
Authors: W. A. See, Q. Xia
Journal: JNCI Journal of the National Cancer Institute (1992)

Background: One objective of regional chemotherapy is to achieve therapeutic drug levels in local tissues and primary nodal drainage fields, while minimizing systemic drug toxicity. The composition of the drug-delivery vehicle may influence local drug absorption and thereby modulate both tissue drug levels and systemic toxicity. Purpose: We evaluated the effect of dimethyl sulfoxide (DMSO) as a drug-delivery vehicle on regional and systemic levels of doxorubicin (DOX) and on the cytotoxicity of DOX following continuous intravesical administration in an invasive rat transitional cell bladder carcinoma model. Methods: F344 rats received continuous intravesical DOX infusion for a 7-day period using a regional drug administration system. A constant dose of DOX was administered in one of three DMSO concentrations (0%, 10%, or 50%) to groups of animals (N=20 per group). These concentrations corresponded to target urinary concentrations of 0%, 0.1%, and 0.5%, respectively. DOX levels in urine, serum, muscle, liver, bladder wall, and retroperitoneal lymph nodes were measured using a fluorescence assay on experimental days 0, 2, 4, 6, and 8 (N = four animals/group per day). In vitro assays evaluated the effect of DMSO concentration on the cytotoxicity of DOX against six transitional cell carcinoma cell lines. A final experiment on rats with established bladder tumors compared the cytoreductive effect of continuous intravesical infusion of DOX in 50% DMSO with that of DOX alone and with that in a sham-treated control group; there were 20 rats in each group. Results: Mean and peak tissue and serum levels of DOX increased as a direct function of DMSO concentration. Compared with the results in controls, mean concentrations of DOX in the bladder were increased 7.1-fold and 12.1-fold in the groups given 10% and 50% DMSO, respectively. Average drug concentrations in the lymph nodes were increased 9.6-fold and 9.3-fold in the groups given 10% and 50% DMSO, respectively. In vitro, DMSO synergistically enhanced the cytotoxicity of DOX in two of the six cell lines studied. Solubilizing the test agent in 5% DMSO reduced the IC 50 (drug concentration required to reduce cell viability to 50% of control values) to an average of 56% ±41% (± SD) of control values; 10% DMSO further decreased the average IC 50 to 20% ± 18% (± SD) of control values. The mean bladder tumor weight of animals treated with the combination of DOX and DMSO was 0.52g. This compared with a mean tumor-bearing bladder weight of 2.69g in the control group (P =.012) and 0.80 g in the group treated with DOX alone (P =.0544). Conclusions: These results suggest that the use of DMSO as a solvent vehicle for DOX improves drug absorption while simultaneously potentiating DOX cytotoxicity. The use of DMSO as a drug carrier merits further evaluation as a way of enhancing the efficacy of regional chemotherapy regimens. (J Natl Cancer Inst 84: 510–515, 1992)